SG11201807979SA - Palatable compositions including sodium phenylbutyrate and uses thereof - Google Patents
Palatable compositions including sodium phenylbutyrate and uses thereofInfo
- Publication number
- SG11201807979SA SG11201807979SA SG11201807979SA SG11201807979SA SG11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA SG 11201807979S A SG11201807979S A SG 11201807979SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bend
- pct
- including sodium
- compositions including
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960002232 sodium phenylbutyrate Drugs 0.000 title abstract 3
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000208140 Acer Species 0.000 abstract 1
- 238000006677 Appel reaction Methods 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 abstract 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 abstract 1
- 208000030162 Maple syrup disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 208000016245 inborn errors of metabolism Diseases 0.000 abstract 1
- 201000008319 inclusion body myositis Diseases 0.000 abstract 1
- 208000015978 inherited metabolic disease Diseases 0.000 abstract 1
- 208000024393 maple syrup urine disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 1
- 208000030954 urea cycle disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308614P | 2016-03-15 | 2016-03-15 | |
| PCT/US2016/057415 WO2017160345A1 (en) | 2016-03-15 | 2016-10-17 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807979SA true SG11201807979SA (en) | 2018-10-30 |
Family
ID=59847918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807979SA SG11201807979SA (en) | 2016-03-15 | 2016-10-17 | Palatable compositions including sodium phenylbutyrate and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20170266115A1 (ar) |
| EP (2) | EP4104822A1 (ar) |
| JP (3) | JP7136763B2 (ar) |
| KR (2) | KR20240119184A (ar) |
| AU (1) | AU2016398029B2 (ar) |
| BR (1) | BR112018068665B1 (ar) |
| CA (1) | CA3017573A1 (ar) |
| DK (1) | DK3429559T3 (ar) |
| ES (1) | ES2922749T3 (ar) |
| HR (1) | HRP20220856T1 (ar) |
| HU (1) | HUE059630T2 (ar) |
| IL (2) | IL296490A (ar) |
| LT (1) | LT3429559T (ar) |
| MX (2) | MX2018011229A (ar) |
| PL (1) | PL3429559T3 (ar) |
| PT (1) | PT3429559T (ar) |
| RS (1) | RS63383B1 (ar) |
| SA (1) | SA518400020B1 (ar) |
| SG (1) | SG11201807979SA (ar) |
| SI (1) | SI3429559T1 (ar) |
| WO (1) | WO2017160345A1 (ar) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE059630T2 (hu) | 2016-03-15 | 2022-11-28 | Acer Therapeutics Inc | Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik |
| US20230248657A1 (en) * | 2020-07-07 | 2023-08-10 | Acer Therapeutics Inc. | Methods of administering taste masked phenylbutyrate and compositions therefor |
| CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
| IT202100019613A1 (it) | 2021-07-23 | 2023-01-23 | Kolfarma S R L | Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale |
| CN216570857U (zh) * | 2021-08-11 | 2022-05-24 | Acer治疗公司 | 改善药物物质适口性的剂型和多个剂型 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| US20040152784A1 (en) * | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| FR2850275B1 (fr) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
| JP2005060310A (ja) * | 2003-08-13 | 2005-03-10 | Towa Yakuhin Kk | 不快な味をマスキングする経口投与用製剤 |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| DE602005003343T2 (de) * | 2004-04-12 | 2008-09-11 | Pfizer Products Inc., Groton | Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln |
| US8821928B2 (en) * | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| ES2332687B1 (es) | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| US20100136110A1 (en) * | 2008-09-30 | 2010-06-03 | Astellas Pharma Inc. | Granular pharmaceutical composition for oral administration |
| PT2456304E (pt) | 2009-07-24 | 2015-10-12 | Baylor College Medicine | Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| EP2389932A1 (en) * | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
| EP2648528B1 (en) | 2010-12-06 | 2016-07-20 | Degama Berrier Ltd. | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| US20140178484A1 (en) * | 2011-05-16 | 2014-06-26 | Sun Pharma Advanced Research Company Ltd. | Multi-particulate pharmaceutical composition |
| JP2012240917A (ja) * | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
| RU2013156437A (ru) | 2011-06-07 | 2015-07-20 | СПАЙ Груп Лтд. | Композиция и способы улучшения стабильности и продления срока хранения чувствительных пищевых добавок и пищевых продуктов из них |
| WO2012175714A1 (en) * | 2011-06-22 | 2012-12-27 | Gmp-Orphan | Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease |
| BR112014003117A2 (pt) | 2011-08-12 | 2017-06-13 | Boehringer Ingelheim Vetmedica Gmbh | inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino |
| EP2599477A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbutyric acid sustained release formulation |
| US8993041B2 (en) * | 2012-10-15 | 2015-03-31 | New Jersey Institute Of Technology | Taste masked active pharmaceutical powder compositions and processes for making them |
| CN105560203A (zh) | 2013-01-28 | 2016-05-11 | 万平 | 定位速释生物粘附剂及其制备方法和应用 |
| JP6147711B2 (ja) * | 2014-05-26 | 2017-06-14 | 富士フイルム株式会社 | 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法 |
| HUE059630T2 (hu) | 2016-03-15 | 2022-11-28 | Acer Therapeutics Inc | Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik |
-
2016
- 2016-10-17 HU HUE16894786A patent/HUE059630T2/hu unknown
- 2016-10-17 KR KR1020247025507A patent/KR20240119184A/ko active Search and Examination
- 2016-10-17 EP EP22167705.7A patent/EP4104822A1/en active Pending
- 2016-10-17 LT LTEPPCT/US2016/057415T patent/LT3429559T/lt unknown
- 2016-10-17 KR KR1020187029452A patent/KR102690703B1/ko active IP Right Grant
- 2016-10-17 AU AU2016398029A patent/AU2016398029B2/en active Active
- 2016-10-17 HR HRP20220856TT patent/HRP20220856T1/hr unknown
- 2016-10-17 CA CA3017573A patent/CA3017573A1/en active Pending
- 2016-10-17 SG SG11201807979SA patent/SG11201807979SA/en unknown
- 2016-10-17 IL IL296490A patent/IL296490A/en unknown
- 2016-10-17 WO PCT/US2016/057415 patent/WO2017160345A1/en active Application Filing
- 2016-10-17 JP JP2019500212A patent/JP7136763B2/ja active Active
- 2016-10-17 PL PL16894786.9T patent/PL3429559T3/pl unknown
- 2016-10-17 US US15/295,881 patent/US20170266115A1/en not_active Abandoned
- 2016-10-17 SI SI201631567T patent/SI3429559T1/sl unknown
- 2016-10-17 RS RS20220651A patent/RS63383B1/sr unknown
- 2016-10-17 BR BR112018068665-4A patent/BR112018068665B1/pt active IP Right Grant
- 2016-10-17 MX MX2018011229A patent/MX2018011229A/es unknown
- 2016-10-17 EP EP16894786.9A patent/EP3429559B1/en active Active
- 2016-10-17 DK DK16894786.9T patent/DK3429559T3/da active
- 2016-10-17 ES ES16894786T patent/ES2922749T3/es active Active
- 2016-10-17 PT PT168947869T patent/PT3429559T/pt unknown
-
2018
- 2018-09-13 SA SA518400020A patent/SA518400020B1/ar unknown
- 2018-09-13 IL IL261777A patent/IL261777B2/en unknown
- 2018-09-14 MX MX2022003969A patent/MX2022003969A/es unknown
-
2020
- 2020-01-17 US US16/746,186 patent/US11433041B2/en active Active
-
2021
- 2021-03-09 US US17/196,599 patent/US11202767B2/en active Active
- 2021-03-09 US US17/196,416 patent/US11154521B2/en active Active
-
2022
- 2022-05-09 JP JP2022076939A patent/JP2022106927A/ja not_active Withdrawn
- 2022-09-02 US US17/902,358 patent/US20230133629A1/en active Pending
-
2024
- 2024-03-29 JP JP2024055290A patent/JP2024081748A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201807979SA (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof |